Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

Revenues for SPARC are expected to rise beyond last year's, potentially signaling a worthwhile investment opportunity. Investors may find the growth compelling if it aligns with other positive fundamentals, as it suggests the company is performing well and may offer good returns on investment.

Financial Ratios:

currentRatio 0.02900
forwardPE 0.00000
debtToEquity 0.00000
earningsGrowth 0.00000
revenueGrowth -0.38900
grossMargins 0.52027
operatingMargins -8.68702
trailingEps -8.23000
forwardEps 55.40000

SPARC's current ratio of 0.029 indicates potential liquidity issues, as the company's cash reserves and current assets may not be enough to cover short-term debts. This raises concerns about SPARC's ability to meet its near-term financial obligations.
Sun Pharma Advanced Research Company Limited's low growth in earnings and revenue points to a likely reduction in profits. This signals a weakening financial performance, indicating the company might face difficulties in staying profitable.

Price projections:

Price projections for SPARC
Price projections for SPARC



Recommendation changes over time:

Recommendations trend for SPARC
Recommendations trend for SPARC


SPARC has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view SPARC as a reliable choice for their money, offering a promising avenue for future growth and financial gains.